Expanded Access to MGAWN1 in Subjects With: Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection and a Compromised Immune System; or Substantial Accidental Exposure to West Nile Virus.

Trial Profile

Expanded Access to MGAWN1 in Subjects With: Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection and a Compromised Immune System; or Substantial Accidental Exposure to West Nile Virus.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2011

At a glance

  • Drugs MGAWN1 (Primary)
  • Indications West Nile virus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jul 2011 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 01 Nov 2010 Status changed from recruiting to suspended, according to ClinicalTrials.gov.
    • 29 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top